Peptides for sleep
No peptide has good evidence for improving sleep. DSIP, the one marketed most directly for it, was the only compound of seven that an FDA advisory committee voted against in July 2026.
The short version
- DSIP: the human studies are old, small and inconsistent, and it has no legal compounding route.
- Sermorelin: sold for sleep and recovery, but the adult studies are small or uncontrolled.
- Epitalon: an FDA advisory committee reviewed it for insomnia and recommended it for compounding, but the human evidence is limited and no dose has been established.
- What does have evidence: persistent insomnia has established treatments, starting with cognitive behavioral therapy for insomnia. A clinician is the better first stop.
Better studied
Grades describe the evidence for a compound's best-studied use, which is not always the use on this page. The summary under each name says what was actually tested. How the grades work.
Sermorelin
Grade B Compounded
Signals your pituitary to release its own growth hormone rather than supplying hormone directly. Prescribed and compounded legally, with modest evidence for the uses it is marketed for.
Little or no human evidence
DSIP
Grade C No legal route
A sleep peptide from the 1970s. In July 2026 it was the only one of seven compounds an FDA advisory committee voted against allowing pharmacies to compound.
Epitalon
Grade C 2026 policy
A four-amino-acid peptide sold for longevity and telomere effects. Legally compoundable in courses since October 2026; the human evidence is old and limited.
What you can legally get
- Compounded on prescription (long-standing): Sermorelin
- Compoundable on prescription under the October 2026 policy: Epitalon
- No legal route in the US: DSIP
Products sold online as "research use only" are outside every one of these routes. See how to vet a provider.
Keep reading
This page summarizes our compound pages. The sources for every claim are listed on each of those pages.